GENINUS Past Earnings Performance
Past criteria checks 0/6
GENINUS's earnings have been declining at an average annual rate of -3.2%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 30.9% per year.
Key information
-3.2%
Earnings growth rate
-2.1%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | -30.9% |
Return on equity | -28.1% |
Net Margin | -139.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How GENINUS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 6,967 | -9,684 | 7,079 | 2,203 |
30 Sep 23 | 6,923 | -9,922 | 5,672 | 3,375 |
31 Dec 22 | 10,083 | -9,385 | 4,659 | 5,327 |
Quality Earnings: A389030 is currently unprofitable.
Growing Profit Margin: A389030 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A389030's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A389030's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A389030 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A389030 has a negative Return on Equity (-28.08%), as it is currently unprofitable.